51. Suppression of allograft rejection with anti-alphabeta T cell receptor antibody in rat corneal transplantation
- Author
-
S, Yamagami, T, Tsuru, T, Ohkawa, H, Endo, and M, Isobe
- Subjects
Graft Rejection ,Receptors, Antigen, T-Cell, alpha-beta ,Graft Survival ,Antibodies, Monoclonal ,Immunohistochemistry ,Rats, Inbred F344 ,Interleukin-10 ,Rats ,Corneal Transplantation ,Mice ,Rats, Inbred Lew ,Rats, Inbred BN ,Animals ,Cytokines ,Interleukin-2 ,Transplantation, Homologous ,Female ,Hypersensitivity, Delayed ,RNA, Messenger - Abstract
Anti-alphabeta T cell receptor monoclonal antibody (R73) has been reported to be a potent immunosuppressant. The suppressive effects of this antibody on allograft rejection after corneal transplantation are unknown.Orthotopic rat penetrating keratoplasty was performed using Lewis rats as recipients and Brown Norway and Fisher rats as donors. The treated groups received R73 intraperitoneally until day 12 after the transplantation. In grafted rats with or without R73 treatment, cytokine expression of the aqueous humor, corneal-infiltrating cells, draining lymph nodes, and splenocytes was determined. Delayed-type hypersensitivity (DTH) responses were compared.All allografts in the untreated controls of Fisher-to-Lewis or BN-to-Lewis rat combinations were rejected within 14 days. In contrast, indefinite survival rates of the postoperative R73-treated group increased to 86% in the Fisher-to-Lewis and 23% in the Brown Norway-to-Lewis combinations, respectively. Interferon-y, interleukin (IL)-2 (T helper [Th]1), and IL-10 (Th2), but not IL-4 (Th2), expression of the eye and DTH responses in the control group were suppressed in the R73-treated group. Both IL-2 and IL-10 expression after mixed lymphocyte culture in the R73-treated group were significantly lower than those of the naive and untreated control group.alphabeta T cell receptor-targeted therapy prevents allograft rejection in rat corneal transplantation as evidenced by suppression of DTH responses. The cytokine profile after R73 treatment was characterized by low interferon-gamma, IL-2, and IL-10, and high IL-4 expression.
- Published
- 1999